We must admit it felt a bit odd this morning as we actually wanted to listen to Abbott’s (NYSE: ABT) earnings call. It felt surreal especially after yesterday’s call by Johnson and Johnson (NYSE: JNJ), a company which once dominated the glucose monitoring space and now for all practical purposes is out of diabetes. Talk about one company going from the penthouse to the outhouse and the other going in the exact opposite direction. As if we needed any more justification for calling this the wacky world of diabetes.
Now onto what was said and the most astonishing . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.